Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, ascending
dose, dose ranging study to evaluate up to three doses of R935788 (50 mg bid, 100 mg bid and
150 mg bid). Approximately 180 patients who have had rheumatoid arthritis for a minimum of 12
months and who have been receiving a weekly methotrexate (MTX) dose for a minimum of 6 months
will be enrolled into the study.